Skip to main content

News Releases & Statements

News Releases & Statements

New Poll: Americans Believe It’s Time to Protect Consumers From Predatory Short-Term Health Plans

Washington, D.C., Jan. 25, 2022 —  An overwhelming majority of adults (79%) believes the government should regulate insurance products that exploit loopholes to discriminate against cancer patients and others with pre-existing conditions, according to a new national survey.

Read More
Burlington

Burlington Stores’ 20th Consecutive In-Store Fundraising Campaign Raises Nearly $3.4 Million for The Leukemia & Lymphoma Society

Funds will provide lifesaving treatments and support The LLS Children’s Initiative research pillar dedicated to pediatric cancer care innovation

Read More

LLS Statement on COVID-19 Omicron Variant for Blood Cancer Patients and Survivors

Rye Brook, N.Y., January 4, 2022 – Given the rapid rise in COVID-19 infections caused by the Omicron variant, The Leukemia & Lymphoma Society has developed this page to provide blood cancer patients and survivors with the latest information about this rapidly emerging situation.

Read More

FDA Approves First Drug for The Prevention of Acute Graft Versus Host Disease

Rye Brook, N.Y., December 15, 2021 – The Food and Drug Administration (FDA) recently approved abatacept (Orencia), in combination with certain immunosuppressants, for the prevention of acute graft versus host disease (aGVHD) in patients 2 years and older who underwent a stem cell transplant from an unrelated donor

Read More

Largest Study to Date Demonstrates Most Blood Cancer Patients Benefit From a Third Primary Dose of mRNA COVID-19 Vaccine

Study supports the Centers for Disease Control and Prevention (CDC) recommendation for immunocompromised adults  

Read More

FDA Approves New Treatment Option for Patients with Multiple Myeloma at First or Subsequent Relapse

Rye Brook, N.Y., December 1, 2021 – The U.S. Food and Drug Administration (FDA) recently granted the seventh approval to daratumumab for the treatment of multiple myeloma. This injectable antibody is approved alone or in combination with other drugs at different states of multiple myeloma treatment.

Read More

LLS Applauds House Passage of Critical Health Reforms

Rye Brook, N.Y., Nov. 19, 2021 — The Leukemia & Lymphoma Society applauds passage of critical patient-friendly reforms by the U.S. House of Representatives. The provisions, components of the Build Back Better Act, represent a key step towards ensuring millions of people — including cancer patients and survivors — have access to quality, affordable healthcare. LLS urges the U.S. Senate to pass these policies without delay.

Read More

FDA APPROVES THE FIRST INTERFERON FOR ADULTS WITH POLYCYTHEMIA VERA

Rye Brook, N.Y., November 16, 2021 – The U.S. Food and Drug Administration (FDA) last week announced approval of ropeginterferon alfa-2b-njft (ropeg, BESREMi®) for the treatment of polycythemia vera (PV). This is the first medication approved for PV that patients can take regardless of their treatment history, meaning it can be used to treat this rare form of cancer early, which may help reduce the risk of progression over time.

Read More

Media Requests

Please send all media-related inquiries and interview requests to mediarelations@lls.org.  An LLS representative will respond as soon as possible.